Phase II study of low dose (weekly) docetaxel and estramustine in elderly males (age ≥75 years) with hormone-refractory prostate cancer or patients age 18 to 74 years with an ECOG performance status of 2 or 3
2005 ◽
Vol 23
(16_suppl)
◽
pp. 4646-4646
◽
2005 ◽
Vol 23
(16_suppl)
◽
pp. 4613-4613
◽